Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENTX vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Captures Overall Composite Edge (47.5 HOLD vs 48.6 HOLD), While EQ Leads 3–1 on Growth & Valuation Pillars

ENTX Overall Winner 6-Pillar Tally: ENTX 1 – 3 EQ (2 Tie) Matrix Metrics: ENTX 4 – 4 EQ

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (47.5/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 4–4 (led by Options & Positioning), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. ENTX trades at $3.31 (N/M Forward P/E, 0.0% operating margin) versus EQ at $1.06 (1.5x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-100.0% vs. -52.3% YoY).
  • Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs EQ
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 53% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
RSI-14: 61.2 · SMA20: $3.13 · SMA50: $2.93
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.06
-5.36% 1D
Market Cap $92.2M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.54β · 89% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 29.0 Fund 55.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.3%), weak momentum, RSI 34
RSI-14: 33.7 · SMA20: $1.32 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (ENTX 1 – 3 EQ)

Columns: Metric · ENTX · EQ
1. Valuation Multiples EQ
Forward P/E N/M 1.5x
Trailing P/E N/M 1.5x
PEG Ratio N/M N/M
EV / Revenue N/M 8.1x
2. Growth & Scale EQ
Revenue Growth (YoY) -100.0% -52.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.4M
Market Cap $571.2M $92.2M
3. Profitability & Quality Tie
Gross Margin N/A 100.0%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -20.3% -59.0%
4. Balance Sheet & Cash Flow EQ
Cash Generation (TTM) -$16M -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage $265M Net Cash $57M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 116.0% (33rd %ile) 261.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (4) vs EQ (4)
Institutional Metric ENTX EQ Criterion Row Edge
Market Capitalization
Scale
$571.2M $92.2M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
-100.0% -52.3% Higher Growth EQ
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-20.3% -59.0% Higher ROE ENTX
52-Week Range Position
Momentum
73% ($1–$4) 9% ($1–$4) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.92β · 53% Vol 1.54β · 89% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite EQ
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 8.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +25.98 pp
ENTX: +9.44% · EQ: -16.54%
3M Horizon ENTX +48.46 pp
ENTX: -3.36% · EQ: -51.82%
6M Horizon ENTX +219.63 pp
ENTX: +166.53% · EQ: -53.1%
1Y Horizon ENTX +19.77 pp
ENTX: +24.72% · EQ: +4.95%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTX Revenue EQ Revenue ENTX Op. Margin EQ Op. Margin Margin Leader
FY2020 $0M N/A -3059.7% N/A ENTX
FY2021 $0M N/A -2139.6% N/A ENTX
FY2022 $0M $20M -9714.2% -393.9% EQ
FY2023 N/A $40M N/A -40.2% EQ
FY2024 $0M $40M -5295.6% -20.1% EQ
FY2025 $0M N/A -27450.0% N/A ENTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 116.0%
IV Percentile 33rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $571.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $92.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs EQ Key Questions & Quantitative Answers

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (47.5/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 4–4 (led by Options & Positioning), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. ENTX trades at $3.31 (N/M Forward P/E, 0.0% operating margin) versus EQ at $1.06 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-100.0% vs. -52.3% YoY). Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EQ leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENTX cumulative revenue shifted N/A while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 8.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.54β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.